Observation Equal to Rituximab Maintenance in Follicular Lymphoma Study

In a clinical trial of patients with follicular lymphoma, rituximab maintenance following induction therapy proved not much better than observation in terms of a survival advantage.

In this trial, researchers wanted to assess the safety and efficacy of a brief rituximab maintenance regimen in 202 patients aged 60 to 75 diagnosed with treatment-naive advanced follicular lymphoma who had responded to induction therapy featuring four cycles of R-FND (rituximab, fludarabine, mitoxantrone and dexamethasone). Patients also received four weekly doses of rituximab as consolidation.

Results not 'statistically significant'

Induction and consolidation brought about high response rates, with overall response rate at 86 percent and complete remission rate at 69 percent.

When that was done, patients were randomized to receive rituximab maintenance (one dose every two months for eight months) or observation.

In the study arm, the rate of two-year progression free survival (PFS) was 81 percent, while it was 69 percent in the observation arm.

With the small number of participants, this difference could not be regarded as statistically significant, according to researchers. There was also no difference in overall survival between the two arms.

During induction therapy, two patients died from toxicity, and during the maintenance regimen, one quarter of patients experienced grade 3 or grade 4 neutropenia.

Wrote Caron A. Jacobson, M.D., and Arnold S. Freedman, M.D., of Dana-Farber Cancer Institute in an accompanying editorial:

Although effective and well tolerated, particularly in an older population, R-FND followed by rituximab consolidation is less likely to find its way into the first-line treatment of this disease ahead of bendamustine plus rituximab. This study does caution against the universal use of rituximab maintenance outside of the contexts in which it has carefully been studied, including after bendamustine plus rituximab.

Source: Healio

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...